TECX Stock — Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. (TECX)

Updated October 16, 2026.

TECX is a Stock. Total return is -94.5% over the past 8.3 years, 309.6 points behind SPY at 215.1%.

Tectonic Therapeutic is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that target G protein coupled receptors (GPCRs) using its proprietary GEODe technology platform. The company's lead program is TX45, a Fc-relaxin fusion molecule for RXFP1 receptor activation, alongside pipeline programs including TX2100 for hereditary hemorrhagic telangiectasia and other GPCR modulators in development. The company does not currently distribute to shareholders and is typical of early-stage biotech stocks, appealing primarily to investors seeking exposure to clinical-stage therapeutic development rather than current income.

TECX performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.5% over the past 8.3 years, 309.6 points behind SPY at 215.1%. Over the past year its total return — price change plus distributions reinvested — is 17.0%. Its deepest 1-year drawdown was 45.6%.

TECX key facts

Asset type

Stock

Asset class

Equity

Inception date

06/21/2018

Distribution frequency

None

Last close

$20.65 (as of 2026-10-16)

Market cap

$403,694,408

Average volume

175416.0

Beta

0.222

Payout ratio

0.0%

EPS

$-4.57

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TECX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 45.6%.

Who may consider TECX — and who may not

It is a weaker fit for investors who need monthly cash flow (TECX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TECX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions